secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001193125-25-132774
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics reports positive ENLIGHTEN 2 Phase 3 trial: LYR-210 meets primary endpoint in CRS (p=0.0078)
--------------------------------------------------------------------------------

- ENLIGHTEN 2 met primary endpoint: LYR-210 improved 3CS composite score vs sham at 24 weeks (-1.13, p=0.0078) in non-polyp patients.
- Key secondary endpoints met in full population: 3CS (p=0.0209) and SNOT-22 (-8.7, p=0.0101) at 24 weeks; SNOT-22 improvement seen from week 4.
- LYR-210 well-tolerated with safety similar to sham; pooled analysis in 64 nasal polyp patients showed positive trends in multiple endpoints.
- Company plans to align with FDA on NDA submission in non-polyp patients and continue development in nasal polyp patients.
- Effective May 27, 2025, company effected a 1-for-50 reverse stock split (ticker unchanged LYRA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000119312525132774/0001193125-25-132774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000119312525132774/d948302d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-132774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer